- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05226169
Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)
Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastric cancer is associated with chronic blood loss, poor nutrition, and surgical interventions interfering with iron absorption, all of which synergistically increase the risk of iron-deficiency anemia (IDA). A retrospective review of gastric cancer reported that at the time of gastric cancer diagnosis, the prevalence of anemia was 58.7% and the overall prevalence of IDA was 40%. Moreover, patients with unresectable locally advanced or metastatic gastric cancer are treated with myelosuppressive chemotherapies, which further increases the risk for anemia.
The absorption of oral iron in gastric cancer patients is limited due to malabsorption, ongoing gastrointestinal bleeding, and lack of adherence to treatment due to dyspepsia, vomiting, abdominal pain, diarrhea, and constipation. Therefore, IV iron may be preferable due to easy administration, effective iron absorption, and infrequent complications in gastric cancer patients.
• There are a number of IV iron formulations in the market; the recommended IV iron preparations are low-molecular-weight iron dextran, ferric gluconate, iron sucrose, ferric carboxymaltose (FCM), and ferumoxytol. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) is a stable colloidal solution of nanoparticles which consist of a polynuclear iron (III)-(oxyhydr)oxide core stabilized by carboxymaltose, which allows slow and prolonged iron release, and is given as a single high-dose (1,000 mg of iron) in a 15-minute infusion. Based on extensive experience in clinical trial and real-world settings, IV FCM is an effective and generally well tolerated treatment for rapidly replenishing iron stores and correcting anemia in patients with ID or IDA of various etiologies.
FCM was effective in patients with active malignancy and IDA (n=420), and hematological malignancies or solid tumors and anemia (n=367) in two real-world, noninterventional studies conducted in Germany and France. Recently, two prospective studies conducted in South Korea have reported a significant increase in Hb levels by treatment with IV FCM in patients with solid cancers (including gastric cancer) receiving chemotherapy and in patients with acute isovolemic anemia following gastrectomy.
Therefore, the main objective of this study is to evaluate the efficacy and safety of IV FCM in patients with AGC receiving palliative chemotherapy. This study will also evaluate the effect of IV FCM on the treatment outcomes of palliative chemotherapy in patients with gastric cancer receiving fluoropyrimidine and platinum-based regimen in the same 1st-line palliative setting.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Min-Hee Ryu, PhD
- Phone Number: 82-2-3010-5935
- Email: miniryu@amc.seoul.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 138-736
- Recruiting
- Asan Medical Center
-
Contact:
- Min-Hee Ryu, MD., Ph.D.
- Phone Number: +82-10-5285-9492
- Email: miniryu@amc.seoul.kr
-
Principal Investigator:
- Min-Hee Ryu, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 19 years at the time of study registration
- Eastern Cooperative Oncology Group performance status ≤ 2
- Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma
- Locally advanced unresectable or metastatic disease
- Patients who have not been treated with palliative systemic antitumor agents for advanced or recurrent gastric or GEJ adenocarcinoma
- Patients scheduled to receive palliative first-line fluoropyrimidine and platinum-based systemic therapy including targeted therapy or immunotherapy
- Life expectancy ≥24 weeks
IDA
- Hb 8 to <11 g/dL
Absolute ID (serum ferritin < 100 ng/mL) OR functional ID (TSAT* < 50% and serum ferritin 100-500 ng/mL)
- TSAT = (serum iron level x 100)/ total iron-binding capacity (TIBC)
Exclusion Criteria:
- Body weight < 35 kg
- Immediate need for transfusion or Hb < 8 g/dL
- Possible functional ID or No ID (serum ferritin > 500 ng/mL OR TSAT ≥ 50%)
- Anemia attributable to factors other than cancer or chemotherapy (e.g., vitamin B12 and/or serum folate deficiency; hemolysis; or myelodysplastic syndromes)
- Ongoing bleeding or overt gross active bleeding (e.g., hematemesis, melena, or hematochezia)
- Neoplastic bone marrow infiltration
- History of ESA, IV or oral iron therapy, and/or RBC transfusion 4 weeks prior to randomization
- Iron overload or disturbances in utilization of iron (e.g., personal or family history of hemochromatosis and hemosiderosis)
- Known hypersensitivity to any of the required study products or known serious hypersensitivity to other parenteral iron products
- Known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergies, and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis)
- Decreased renal function including renal dialysis (previous, current or planned within the next 6 months,) or serum creatinine levels ≥ 2.0 mg/dL, or estimated glomerular filtration rate < 30 mL/min/1.73 m2
- Chronic liver disease (including active hepatitis) and/or aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 times the upper limit of the normal range
- Active acute or chronic infections (assessed by clinical judgment)
- Other significant medical condition(s) in the opinion of the investigator with an anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject or may interfere with study assessments, outcomes (e.g., uncontrolled hypertension, active cardiac disease, thromboembolic disease, or uncontrolled diabetes mellitus, neurological or psychiatric disorders)
- Pregnancy (e.g., positive human chorionic gonadotropin test) or breast-feeding. If the subject is of childbearing potential and does, not use adequate contraceptive precautions. The subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active treatment arm : IV FCM
Intravenous ferric carboxymaltose
|
Other Names:
|
Active Comparator: Control treatment arm: Conservative management
Conservative management
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum change of Hb concentration
Time Frame: baseline to 12 weeks
|
Maximum change of Hb concentration from baseline to 12 weeks (or first RBC transfusion and/or ESA, or study withdrawl, or death, whichever will be first) without RBC transfusion and/or ESA
|
baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Hb concentration
Time Frame: baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change of Hb concentration from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum iron
Time Frame: baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum iron from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum ferritin
Time Frame: baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum iron, ferritin(ng/dL) from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum TIBC
Time Frame: baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum TIBC(µg/dL) from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum TSAT
Time Frame: baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Change in serum TSAT(%) from baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
baseline to 3, 6, 9, 12, 24, 36, and 48 weeks
|
Tumor response
Time Frame: every 6-8weeks, assessed up to 24 months
|
according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
|
every 6-8weeks, assessed up to 24 months
|
PFS
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
time from the date of first administration of palliative first-line chemotherapy to the date of the first objectively documented tumor progression or death, whichever occurs first)
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
OS
Time Frame: through study completion, an average of 2 years
|
time from the date of first administration of palliative first-line chemotherapy to the date of death due to any cause
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMC2102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Gastric Carcinoma
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingAdvanced Solid Tumor | Advanced Gastric Carcinoma | Advanced Cholangiocarcinoma | Advanced Lung CancerChina
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
The Affiliated Hospital of Qingdao UniversityRecruitingGastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line TherapyChina
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedAdvanced Gastric CarcinomaBangladesh
-
Lin ChenCompletedImmunotherapy | Advanced Gastric CarcinomaChina
-
Shanghai Minimally Invasive Surgery CenterWuxi Branch of Ruijin Hospital; Shanghai OneTar Biomedicine Co., Ltd.Not yet recruiting
-
Tianjin Medical University Cancer Institute and...RecruitingFirst-line Treatment | Advanced Gastric CarcinomaChina
-
Hospices Civils de LyonRecruitingGastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic AdenocarcinomaFrance
-
Henan Cancer HospitalRecruitingAdvanced Gastric AdenocarcinomaChina
Clinical Trials on Ferinject
-
National Cancer Center, KoreaJW PharmaceuticalCompletedAnemia | Pancreatic CancerKorea, Republic of
-
Samsung Medical CenterUnknown
-
Vifor PharmaParexelCompletedIron Deficiency | Inflammatory Bowel DiseaseRussian Federation
-
Jomo Kenyatta University of Agriculture and TechnologyCompletedIron Deficiency Anemia | COVID-19 Vaccine | Iron Deficiency Anemia Treatment | Vaccine Response ImpairedKenya
-
Swiss Federal Institute of TechnologyJomo Kenyatta University of Agriculture and TechnologyCompletedIron Deficiency Anemia | Vaccine Preventable Disease | Iron Deficiency Anemia Treatment | Vaccine Response ImpairedKenya
-
University Hospital MuensterVifor PharmaTerminatedAnemia | Orthopedic Surgery | High Risk of Blood LossGermany
-
St Joseph University, Beirut, LebanonSaint-Joseph University; Vifor PharmaCompletedAnemia, Iron DeficiencyLebanon
-
University of ZurichVifor PharmaTerminatedIron Deficiency AnemiaSwitzerland
-
Vifor PharmaSGS S.A.Completed
-
The Catholic University of KoreaUnknownKnee Osteoarthritis | Total Knee Arthroplasty | Postoperative Anemia